$SGP News

SpyGlass Says AMA CPT Editorial Panel Approves New Add-On Category III CPT Code For Attachment, Insertion Of Intraocular Lens Prosthesis-Mounted Drug-Eluting Implant

SpyGlass Pharma Q1 EPS $(0.69) Misses $(0.42) Estimate

SpyGlass Pharma shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

SpyGlass Pharma shares are trading lower after the company reported a year-over-year decrease in Q4 financial results.

SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update

SpyGlass Pharma Q4 EPS $(5.72) Down From $(4.58) YoY

HC Wainwright & Co. Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $37

SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System

SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment

SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit

Citigroup Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42

Leerink Partners Initiates Coverage On SpyGlass Pharma with Outperform Rating, Announces Price Target of $42

Jefferies Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $62

Stifel Initiates Coverage On SpyGlass Pharma with Buy Rating, Announces Price Target of $42

SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Reported Earlier, SpyGlass Pharma Prices Initial Public Offering Of 9.375M Common Shares At $16.00 Per Share For ~$150M Gross Proceeds

SpyGlass Pharma Announces Pricing of Initial Public Offering

Spyglass Pharma, Inc To Start Trading Tomorrow

SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates